Mainstay confirms its continued eligibility to the PEA-PME

on 30/01/2017 16:58

Mainstay Medical Applies for Approval to Market ReActiv8 in Australia

on 12/01/2017 16:53
Application for inclusion in Australian Register of Therapeutic Goods a key step towards commercialization of innovative treatment of Chronic Low Back Pain in Australian market
Read more

Nexstim to present at Biotech Showcase 9th Annual Conference in San Francisco

on 05/01/2017 11:36

Ogeda announces fezolinetant as INN and issuance of US patent for ESN364

on 20/12/2016 10:45

Confo Therapeutics to appoint John Berriman as Chairman of the Board

on 15/12/2016 16:58